Investigation of epigenetic modifier on HDAC1 and microRNA-410 expression in ovarian cancer cell lines

• Published in: Gene reports 2021-09, Vol.24, p.101240, Article 101240
• Main Authors: Sarkargar, Fatemeh, Mazaheri, Mahta, Zare, Aniseh, Hajihosseini, Reza
• Format: Article
• Language: English
• Subjects: Chemotherapy agents; HDAC1; miRNA-410; Ovarian cell lines
• ISSN: 2452-0144; 2452-0144
• DOI: 10.1016/j.genrep.2021.101240

The purpose of this study was in vitro evaluation of 5-Aza-2′-Deoxycytidine (5-Aza-dC), Trichostatin A (TSA) and Cisplatin effects on HDAC1 gene and miRNA-410 expression in ovarian cancer cell lines and comparing with cotreatment results on gene expression. Influence of 5-Aza-2′-Deoxycytidine, TSA and Cisplatin on human cells was evaluated alone and together. We measured HDAC gene and miR-410 expression by Quantitative Real Time polymerase chain reactions (qRT-PCR) and the results were analyzed by SPSS and GraphPad Prism 7 software. While each drug effects the expression of HDAC1 and miRNA-410, their coadministration had more effective results. Cisplatin, TSA, and 5-Aza-dC have a great potential in terms of therapeutic agents in ovarian cancer patients; however, more studies are needed to optimize their specificity and effectiveness. •Epigenetic drugs include 5-aza- cytidine in ovarian cancer may provide a hopeful treatment for patients.•Downregulation of tumor suppressor microRNAs maybe increasing expression of Histone Deacetylase 1.•Down-regulation of miR-410 has a critical role in tumor progression, since its overexperssion leads to a reduced cell growth.•Targeting the miR-410 and HDAC using 5-Aza-dC might be a novel therapeutic approach in chemoresistant ovarian cancer.